Trajectories of Situational Temptations in Pregnant Smokers participating in a Scheduled Gradual Reduction Cessation Trial

Approximately 15% of US women currently smoke during pregnancy. An important step toward providing effective smoking cessation interventions during pregnancy is to identify individuals who are more likely to encounter difficulty quitting. Pregnant smokers frequently report smoking in response to intrapersonal factors (e.g., negative emotions), but successful cessation attempts can also be influenced by interpersonal factors (i.e., influence from close others). This study examined the association between emotion regulation difficulties, positive and negative social control (e.g., encouragement, criticism), and smoking cessation-related variables (i.e., smoking quantity, withdrawal symptoms) among pregnant smokers. Data were drawn from the pretreatment wave of a smoking cessation trial enrolling low-income pregnant women who self-reported smoking in response to negative affect (N = 73). Greater emotion regulation difficulties were related to greater smoking urges (b = 0.295, p = .042) and withdrawal symptoms (b = 0.085, p = .003). Additionally, more negative social control from close others was related to fewer smoking days (b = -0.614, p = .042) and higher smoking abstinence self-efficacy (b = 0.017, p = .002). More positive social control from close others interacted with negative affect smoking (b = -0.052, p = .043); the association between negative affect smoking and nicotine dependence (b = 0.812, p < .001) only occurred at low levels of positive social control. Findings suggest that emotion regulation difficulties may contribute to smoking during pregnancy by exacerbating women's negative experiences related to smoking cessation attempts. Negative social control was related to lower smoking frequency and greater confidence in quitting smoking, suggesting that it may assist pregnant smokers' cessation efforts. Positive social control buffered women from the effects of negative affect smoking on nicotine dependence.

Download Full-text

Metabolic Adaptation to a Gradual Reduction in Myocardial Blood Flow

Circulation ◽

10.1161/01.cir.92.2.244 ◽

1995 ◽

Vol 92 (2) ◽

pp. 244-252 ◽

Cited By ~ 31

Author(s):

Andrew E. Arai ◽

Susan E. Grauer ◽

Cheryl G. Anselone ◽

George A. Pantely ◽

J. David Bristow

Keyword(s):

Blood Flow ◽

Myocardial Blood Flow ◽

Metabolic Adaptation ◽

Gradual Reduction

Download Full-text

Effects of nicotine patch or nasal spray on nicotine and cotinine concentrations in pregnant smokers

The Journal of Maternal-Fetal & Neonatal Medicine ◽

10.3109/14767050902994515 ◽

2009 ◽

Vol 22 (9) ◽

pp. 751-758 ◽

Cited By ~ 20

Author(s):

Cheryl Oncken ◽

Winston Campbell ◽

Grace Chan ◽

Dorothy Hatsukami ◽

Henry R. Kranzler

Keyword(s):

Nasal Spray ◽

Nicotine Patch ◽

Pregnant Smokers

Download Full-text

Pregnant Smokers’ Intention to Switch From Cigarettes to E-Cigarettes: A Reasoned Action Approach

Women s Health Issues ◽

10.1016/j.whi.2021.07.005 ◽

2021 ◽

Author(s):

Page D. Dobbs ◽

Paul Branscum ◽

Amy M. Cohn ◽

Alayna P. Tackett ◽

Ashley L. Comiford

Keyword(s):

Reasoned Action ◽

Reasoned Action Approach ◽

Pregnant Smokers

Download Full-text

Helping pregnant smokers to quit

BMJ ◽

10.1136/bmj.g1808 ◽

2014 ◽

Vol 348 (mar11 3) ◽

pp. g1808-g1808 ◽

Cited By ~ 1

Author(s):

L. S. Brose

Keyword(s):

Pregnant Smokers

Download Full-text

A gradual reduction of female structures in the pistillate flowers ofRicinus communis L. (castor-bean) with chlorflurenol (morphactin)

Biologia Plantarum ◽

10.1007/bf02902863 ◽

1982 ◽

Vol 24 (2) ◽

pp. 152-154 ◽

Cited By ~ 4

Author(s):

Mary Varkey ◽

R. K. Nigam

Keyword(s):

Castor Bean ◽

Gradual Reduction

Download Full-text

RARE-25. RETINAL ASTROCYTOMA mTOR INHIBITOR THERAPY IN TUBEROUS SCLEROSIS MOSAICISM

Neuro-Oncology ◽

10.1093/neuonc/noaa222.736 ◽

2020 ◽

Vol 22 (Supplement_3) ◽

pp. iii447-iii447

Author(s):

Naomi Evans ◽

Katherine Paton ◽

Harinder Kaur Gill ◽

Juliette Hukin

Keyword(s):

Optic Nerve ◽

Retinal Detachment ◽

Tuberous Sclerosis ◽

Tuberous Sclerosis Complex ◽

Mtor Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Neovascular Glaucoma ◽

Renal Angiomyolipoma ◽

Gradual Reduction ◽

Health Canada

Abstract INTRODUCTION Everolimus is an inhibitor of mTORC1 (mammalian target of rapamycin complex 1), it is Health Canada and FDA approved for SEGA and renal angiomyolipoma in the setting of tuberous sclerosis complex (TSC). There is little data available in regards to this treatment of TSC associated retinal astrocytoma (RA). Although the behaviour of RA is often indolent or slowly progressive, aggressive behaviour with retinal detachment and neovascular glaucoma requiring enucleation has been reported in several patients. Definite TSC diagnosis is established when either two major features or one major and two minor features are present. Probable TSC diagnosis is established when one major plus one minor feature is present. METHODS We report a child with probable TSC mosaicism, with negative serum NGS for TSC but RA and retinal achromic patch on the left. A left retinal peripapillary astrocytoma around optic nerve and very close to fovea was noted. There was concern that if it grew or there were to be any leakage it would cause visual impairment. This lead to therapy with everolimus 4.5 mg/m2/d aiming for level between 5 and 10 mcg/L. RESULTS This boy has had a gradual reduction of the RA over the last 29 months, with healthy retina in the region no longer occupied by the lesion and preserved vision. He has tolerated therapy well with occasional mouth ulcers. CONCLUSION mTORC1 inhibition is effective therapy to preserve vision in the setting of retinal astrocytoma and tuberous sclerosis mosaicism.

Download Full-text

Treatment of Seborrhoeic Dermatitis of the Scalp with Desonide 0.05% Solution

European Journal of Inflammation ◽

10.1177/1721727x0300100207 ◽

2003 ◽

Vol 1 (2) ◽

pp. 91-94 ◽

Cited By ~ 1

Author(s):

N. Cassano ◽

G. Alessandrini ◽

D. Fai ◽

M. Gabbellone ◽

M. Gravante ◽

...

Keyword(s):

The Other ◽

Short Term ◽

Gradual Reduction ◽

Once Daily ◽

Seborrhoeic Dermatitis ◽

Topical Corticosteroids ◽

Scalp Lesions ◽

Term Management ◽

Overall Effectiveness

Topical corticosteroids are commonly used for the short-term management of seborrhoeic dermatitis (SD) of the scalp. The aim of this study was to evaluate the effectiveness, tolerance and cosmetic acceptability of desonide 0.05% solution, whose alcohol-free formulation is innovative with respect to traditional corticosteroid lotions, in the treatment of SD of the scalp. For this purpose, 155 adult subjects applied on scalp lesions desonide once daily for 1 week, on alternate days for 3 weeks, and two times a week for 4 weeks. A significant reduction of the severity of erythema, scaling and pruritus was observed (P<0.001). Interestingly, during the phase of gradual reduction of weekly applications, results were frequently maintained or improved further. Twenty patients (13%) at 4 weeks and 85 patients (58%) at 8 weeks had their scalp SD cleared. Most patients regarded the overall effectiveness, tolerability and acceptability as satisfactory; patients who had previously used common steroid lotions expressed a positive judgment on desonide solution compared to the other lotions in terms of efficacy, acceptability, rapidity of action, tolerability and persistence of effects. In conclusion, our preliminary findings indicate that desonide 0.05% solution is suitable for the short-term management of scalp SD.

Download Full-text